NRS indicates numeric rating scale.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Darnall BD, Ziadni MS, Stieg RL, Mackey IG, Kao M, Flood P. Patient-Centered Prescription Opioid Tapering in Community Outpatients With Chronic Pain. JAMA Intern Med. 2018;178(5):707–708. doi:10.1001/jamainternmed.2017.8709
The risks associated with prescription opioids are well described.1,2 Although reducing opioid use is a national priority, existing opioid tapering models use costly interdisciplinary teams that are largely inaccessible to patients and their physicians.3,4 Patients and physicians need solutions to successfully reduce long-term prescription opioid dosages in settings without behavioral services. We conducted a study of voluntary, patient-centered opioid tapering in outpatients with chronic pain without behavioral treatment.
Patients with non–cancer-related chronic pain prescribed long-term opioids at a community pain clinic were provided education about the benefits of opioid reduction (reduced health risks without increased pain) by their prescribing physician. Physicians offered to partner with patients to slowly reduce their opioid dosages over 4 months. The only exclusion was current treatment for substance use disorder. The study was approved by the Stanford University institutional review board; participants provided written or electronic informed consent, and no compensation was provided to participants.
Of the 110 eligible patients, 82 (75%) agreed to taper their opioid dosages; of those, 68 provided baseline demographics, information on opioid use, pain, marijuana use and psychosocial measures. Patients received a self-help book on reducing opioid use, and a slow, individually designed taper. Opioid dosages were reduced up to 5% for up to 2 dose reductions in month 1 to minimize negative physical and emotional response, withdrawal symptoms, and to facilitate patient confidence in the process. In months 2 to 4, patients were asked to further reduce use by as much as 10% per week; dose decrements were tailored to the patient. Patient responses were monitored with close clinical follow-up (at least monthly) and doses adjusted accordingly. Follow-up surveys were administered at 4 months; patients who provided data at 4 months were considered study completers. We confirmed patient-reported opioid prescription with medical record review. We documented patient compliance and accuracy of reported medication use with periodic urine drug testing and continuous monitoring of the state Prescription Drug Monitoring Program (PDMP). No compliance issues or aberrant prescriptions were noted. We converted opioid doses to morphine equivalent daily dose (MEDD). Change in MEDD from baseline was the primary outcome and pain intensity was a secondary outcome. Kruskal-Wallis rank sum test was used for continuous variables and χ2 test for polychotomous variables.
The patients’ mean (SD) age was 51 (12) years, and 41 (60%) were female. Thirty-one of 82 enrolled patients (38%) did not complete a 4-month follow-up survey and therefore were considered to have dropped out of the study. Depression negatively correlated (P = .05) and baseline marijuana use positively correlated (P = .04) with study completion. The Table provides characteristics and results for the sample; we found no sex association with study completion or opioid reduction.
Among study completers (n = 51) baseline median MEDD (interquartile range [IQR]) was 288 (153-587) mg, with a median 6-year duration (IQR, 3-9) duration of opioid use. Median pain intensity was moderate (5 out of 10 on a numeric pain rating). After 4 months, the median MEDD was reduced to 150 (IQR, 54-248) mg (P = .002). The likelihood of a greater than 50% opioid dose reduction was not predicted by starting dose, baseline pain intensity, years prescribed opioids, or any psychosocial variable. Neither pain intensity (P = .29) nor pain interference (P = .44) increased with opioid reduction. The Figure shows the relationship between percentage change in MEDD and pain intensity in study completers.
Our findings suggest that a substantial fraction of patients at a pain clinic may wish to engage in voluntary opioid tapering. Our data challenge common notions that patients taking high-dose opioids will fail outpatient opioid tapers or that duration of opioid use predicts taper success. Combining patient education about the benefits of opioid reduction with a plan that reduces opioids more slowly than current tapering algorithms5 with close clinician follow-up may help patients engage and succeed in voluntary outpatient tapering. Because our data are generated from a single pain clinic, studies are needed to assess how well our protocol would generalize to other types of patients and settings.
Open Access: This article is published under the JN-OA license and is free to read on the day of publication.
Accepted for Publication: December 23, 2018.
Published Online: February 19, 2018. doi:10.1001/jamainternmed.2017.8709
Correction: This article was corrected on April 18, 2022, to clarify Dr Darnall’s Conflict of Interest Disclosures.
Corresponding Author: Beth D. Darnall, PhD, Division of Pain Medicine, Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, 1070 Arastradero Rd, Ste 200, MC 5596, Palo Alto, CA 94304 (firstname.lastname@example.org).
Author Contributions: Dr Darnall had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Darnall, Stieg.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Darnall, Mackey, Flood.
Critical revision of the manuscript for important intellectual content: Darnall, Ziadni, Stieg, Kao.
Statistical analysis: Darnall, Kao, Flood.
Administrative, technical, or material support: Darnall, Ziadni, Stieg, Mackey, Kao.
Study supervision: Darnall, Stieg.
Conflict of Interest Disclosures: Dr Darnall reported serving as a consultant for Axial Health regarding the development of physician education materials on opioid prescribing and safety, receiving shares from the company, and that payments for consulting services were paid to Stanford University; serving on the advisory board for Clinical Pain Advisor, an online pain media outlet, and that compensation for her services was paid to Stanford University; receiving royalties from 2 books on patient self-help for opioid reduction and pain management for chronic pain; and receiving from Tarsus and Neurovations travel reimbursements to present pain research findings at the PainWeek conference and the Kauai Pain Conference, respectively.
Funding/Support: We acknowledge support from National Institutes of Health (NIH): National Center for Complementary and Integrative Health (NCCIH) grants P01AT006651S1 and NCCIH R01AT008561 (Dr Darnall), and NIH grant T32 035165 (Dr Ziadni).
Role of the Funder/Sponsor: The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.